Acumen Pharmaceuticals, Inc.
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Operating Activities | ||||||
| Net Income | $-121.3M | $-102.3M | $-52.4M | $-42.9M | $-100.6M | $-7.3M |
| Depreciation & Amortization | — | — | — | — | — | — |
| Depreciation | $58.0K | $63.0K | $61.0K | $32.0K | $4.0K | — |
| Amortization | — | — | — | — | — | — |
| Stock-Based Compensation | $9.9M | $9.6M | $6.1M | $3.1M | $922.0K | $154.0K |
| Net Cash from Operating Activities | $-115.5M | $-86.2M | $-43.1M | $-35.2M | $-18.0M | $-7.5M |
| Investing Activities | ||||||
| Capital Expenditures | $88.0K | $16.0K | $21.0K | $161.0K | $40.0K | — |
| Business Acquisitions | — | — | — | — | — | — |
| Net Cash from Investing Activities | $133.9M | $48.0M | $-171.7M | $39.2M | $-104.1M | — |
| Financing Activities | ||||||
| Dividends Paid | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — |
| Net Cash from Financing Activities | $-34.0K | $6.9M | $151.8M | $3.9M | $200.5M | $44.7M |
| Net Change in Cash | — | — | — | — | — | — |
| Free Cash Flow | $-115.6M | $-86.2M | $-43.1M | $-35.3M | $-18.0M | — |